Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Pairing hormone therapy with GLP-1 drugs like semaglutide could meaningfully boost weight loss for midlife women, a new study suggests. Researchers found women using both treatments lost significantly more weight than those on GLP-1s alone — and kept it off longer. Still, experts stress that hormone therapy isn't a weight-loss drug, and treatment should always be tailored to the individual.
A large real-world study presented at The Menopause Society's annual meeting found that menopausal women using both hormone therapy (HT) and GLP-1 receptor agonists — like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) — lost significantly more weight than those on GLP-1s alone. The effect appeared as early as 9 months into treatment and held steady through the full follow-up period.
The retrospective cohort study, led by Dr. Regina Castaneda of Mayo Clinic, included 2,379 women aged 45+ with a BMI of at least 27. Researchers theorize that estrogen may amplify GLP-1's appetite-suppressing effects, though they caution the study is observational and cannot prove causation. A "healthy-user" effect — where HT users tend to be more health-engaged overall — may also play a role.
By the Numbers:
Why it matters: Midlife women face a convergence of hormonal shifts, metabolic slowdown, and rising cardiometabolic risk. This study opens the door to more personalized obesity management strategies — but experts are clear: HT is not a weight-loss treatment, and clinical decisions should be driven by each patient's symptoms, health history, and goals.
